Last reviewed 2026-04-23 · How we verify

Havrix®720

Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.

Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in adults and children.

At a glance

Mechanism of action

The vaccine contains inactivated (killed) hepatitis A virus antigen, which triggers both humoral and cellular immune responses without causing disease. This leads to the production of protective anti-HAV antibodies and immunological memory, conferring long-term immunity against hepatitis A infection. The 720 designation refers to the antigen content (720 ELISA units per 0.5 mL dose).

Approved indications

• Prevention of hepatitis A infection in adults and children

Common side effects

• Injection site soreness
• Headache
• Fatigue
• Myalgia
• Fever

Key clinical trials

• Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population (PHASE3)
• Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines (PHASE3)
• Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Havrix®720 CI brief — competitive landscape report
• Havrix®720 updates RSS · CI watch RSS
• Valneva Austria GmbH portfolio CI